RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models

• 主要な著者: Uwe Grether (著者), Richard H. Foxton (著者), Sabine Gruener (著者), Claudia Korn (著者), Atsushi Kimbara (著者), Anja Osterwald (著者), Elisabeth Zirwes (著者), Sabine Uhles (著者), Janina Thoele (著者), Nadine Colé (著者), Mark Rogers-Evans (著者), Stephan Röver (著者), Matthias Nettekoven (著者), Rainer E. Martin (著者), Jean-Michel Adam (著者), Jürgen Fingerle (著者), Caterina Bissantz (著者), Wolfgang Guba (著者), André Alker (著者), Anna M. Szczesniak (著者), Ross F. Porter (著者), Tom J. Toguri (著者), Franco Revelant (著者), Agnès Poirier (著者), Camille Perret (著者), Lotte Winther (著者), Antonello Caruso (著者), Filomena Fezza (著者), Mauro Maccarrone (著者), Melanie E. M. Kelly (著者), Sascha Fauser (著者), Christoph Ullmer (著者)
• フォーマット: 図書
• 出版事項: Frontiers Media S.A., 2024-07-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

IntroductionPreclinical studies suggest that cannabinoid receptor type 2 (CB2R) activation has a therapeutic effect in animal models on chronic inflammation and vascular permeability, which are key pathological features of diabetic retinopathy (DR). A novel CB2R agonist, triazolopyrimidine RG7774, w...